Core Viewpoint - Firefly Aerospace Inc. is facing a class action lawsuit due to alleged violations of securities laws, with claims that the company misrepresented its business prospects and financial performance during its IPO and subsequent reporting period [1][3][4]. Company Overview - Firefly Aerospace operates in the space and defense technology sector, providing mission solutions for national security, government, and commercial customers [2]. IPO Details - The company conducted its initial public offering (IPO) on August 7, 2025, issuing approximately 19.3 million shares at an offering price of $45.00 per share [2]. Allegations of Misrepresentation - The lawsuit alleges that Firefly Aerospace overstated demand and growth prospects for its Spacecraft Solutions offerings, as well as the operational readiness and commercial viability of its Alpha rocket program [3]. Financial Performance - In its first earnings report as a public company on September 22, 2025, Firefly Aerospace reported a loss of $80.3 million for Q2 2025, compared to a loss of $58.7 million in Q2 2024. Revenue was reported at $15.55 million, below analyst estimates of $17.25 million, and down 26.2% year-over-year [4]. - The Spacecraft Solutions business segment reported revenue of only $9.2 million, representing a 49% year-over-year decrease [4]. Stock Price Impact - Following the earnings report, Firefly Aerospace's stock price fell more than 15%. Additionally, on September 29, 2025, the company disclosed an issue with its Alpha Flight 7 rocket, leading to a further decline of over 20% in its stock price [4][5].

Core Points - A class action securities lawsuit has been filed against KBR, Inc. to recover losses for shareholders affected by alleged securities fraud between May 6, 2025, and June 19, 2025 [2][3] - The complaint alleges that KBR, Inc. made false statements regarding its partnership with HomeSafe, despite knowing that the U.S. Department of Defense had concerns about HomeSafe's ability to fulfill a global household goods contract [3] - The lawsuit claims that KBR's statements about its business operations and prospects were materially false and misleading, lacking a reasonable basis during the relevant time [3] Next Steps - Shareholders who suffered losses in KBR, Inc. stock during the specified timeframe are encouraged to learn about their rights to seek recovery, with no cost or obligation to participate [4] Legal Representation - Levi & Korsinsky LLP is a nationally recognized securities litigation firm with a strong track record in securing recoveries for shareholders, having ranked in the Top 50 Report for seven consecutive years [5]

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud that affected shareholders between January 8, 2024, and September 17, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that DexCom made false statements and concealed material design changes to its glucose monitoring products, the G6 and G7, which were unauthorized by the U.S. Food and Drug Administration [3]. - It is alleged that these design changes made the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [3]. - The complaint asserts that the enhancements to the G7, along with its reliability, accuracy, and functionality, were overstated, and the true scope of the issues was downplayed [3]. Group 2: Implications - The alleged actions have subjected DexCom to increased regulatory scrutiny and potential enforcement actions, leading to significant legal, reputational, and financial harm [3]. - The public statements made by the defendants are claimed to have been materially false and misleading throughout the relevant period [3]. Group 3: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. Group 4: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a history of securing substantial recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [5].

Did You Suffer Losses in Perrigo Company plc (PRGO)? Contact Levi & Korsinsky About Securities Fraud ClaimsNovember 13, 2025 3:32 PM EST | Source: Levi & Korsinsky, LLPNew York, New York--(Newsfile Corp. - November 13, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Perrigo Company plc ("Perrigo Company plc") (NYSE: PRGO) concerning possible violations of federal securities laws.Perrigo issued a press release on November 5, 2025, "announc[ing] that it is i ...

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, Incorporated, alleging securities fraud that affected shareholders between December 27, 2023, and May 6, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that Cytokinetics made materially false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten [3]. - Defendants indicated that they expected FDA approval for aficamten's NDA in the second half of 2025, based on a PDUFA date of September 26, 2025, while failing to disclose risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [3][4]. - During an earnings call on May 6, 2025, it was disclosed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [4]. Group 2: Impact on Shareholders - As a result of the alleged false statements, shareholders purchased Cytokinetics' common stock at inflated prices and incurred significant losses when the truth about the NDA submission was revealed [5]. - Shareholders who suffered losses during the relevant timeframe are encouraged to seek recovery, with no cost or obligation to participate [6]. Group 3: Legal Representation - Levi & Korsinsky LLP, a nationally recognized securities litigation firm, has a strong track record in securing recoveries for shareholders and has been ranked among the top securities litigation firms in the United States for seven consecutive years [7].

Core Viewpoint - Ardent Health, Inc. is under investigation for potential violations of federal securities laws following a significant revenue drop and a 33% decline in stock price [1][3][4]. Financial Performance - In Q3 2025, Ardent reported a $43 million decrease in revenue due to "hindsight evaluations of historical collection trends" [4]. - The company also increased its professional liability reserves by $54 million due to adverse prior period claim developments from 2019 to 2022 and broader industry trends [4]. Stock Market Reaction - Following the financial results announcement on November 12, 2025, Ardent's stock price fell over 33% during trading on November 13, 2025 [4]. Legal Implications - Bleichmar Fonti & Auld LLP has initiated an investigation into Ardent Health, Inc. for potential securities fraud, urging affected investors to contact them for more information [1][2][5].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for allegedly misleading investors regarding its operations and financial performance during the specified Class Period from October 22, 2024, to October 28, 2025 [1][3]. Company Overview - Stride, Inc. is an education technology company based in Reston, Virginia, providing online learning programs, curricula, and support services to schools and districts across the United States [2]. Allegations - The lawsuit claims that Stride inflated enrollment numbers, reduced staffing below statutory limits, ignored compliance requirements, and concealed enrollment losses during the Class Period [3]. - The truth about Stride's situation was revealed on September 14, 2025, when a school district sued the company for fraud and deceptive trade practices [4]. - On October 28, 2025, Stride announced that "poor customer experience" led to increased withdrawal rates and decreased enrollments, which significantly impacted the company's stock price [4].

Core Viewpoint - A class action lawsuit has been filed against KBR, Inc. for allegedly making false and misleading statements regarding its partnership with HomeSafe, which led to a significant drop in KBR's stock price after the termination of a contract by the U.S. Department of Defense's TRANSCOM [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired KBR shares between May 6, 2025, and June 19, 2025 [1][2]. - Investors have until November 18, 2025, to seek appointment as lead plaintiff representatives [2]. - The allegations include KBR's failure to disclose concerns from TRANSCOM about HomeSafe's ability to fulfill its obligations under the Global Household Goods Contract [3]. Group 2: Impact on Stock Price - Following the announcement of the contract termination by HomeSafe on June 19, 2025, KBR's shares fell by $3.85, or 7%, closing at $48.93 on June 20, 2025 [4]. Group 3: Company Background - KBR, Inc. is headquartered in Houston, Texas, and provides engineering, logistics, defense contracting, and mission-critical government services [2].

Core Viewpoint - Kehoe Law Firm, P.C. is investigating potential breaches of fiduciary duties by certain board members and executive officers of Priority Technology Holdings, Inc. in relation to a proposal to take the company private at a price below market value [1][2]. Group 1: Investigation Details - The investigation centers on a proposal by CEO Thomas Priore to acquire publicly held shares of Priority Technology for $6.00-$6.15 per share [2]. - This proposed price is significantly lower than the company's 52-week average price of $8.19 and high price of $12.47, as well as below the average and high Street price targets of $10.80 and $13.00, respectively [3]. Group 2: Company Background - Priority Technology Holdings, Inc. is publicly traded on NASDAQ under the ticker PRTH [2]. - Kehoe Law Firm, P.C. is a recognized plaintiff-side class action firm that focuses on protecting investors and consumers from fraud and misconduct, having recovered over $10 billion for investors [3][4].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for alleged violations of federal securities laws, focusing on misleading statements regarding the company's products and services [1][2]. Class Definition - The lawsuit seeks damages for all individuals and entities that purchased Stride securities between October 22, 2024, and October 28, 2025, inclusive [2]. Case Details - The Complaint alleges that Stride made misleading statements about its educational products and services, claiming they help learners reach their full potential while engaging in practices such as: - Inflating enrollment numbers by retaining "ghost students" - Cutting staffing costs by overloading teachers beyond statutory limits - Ignoring compliance requirements, including background checks and special education services - Suppressing whistleblowers who reported financial directives to delay hiring and deny services - Losing existing and potential enrollments [3]. Next Steps - Interested parties can review the Complaint and have until January 12, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. Legal Representation - The law firm Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only collect fees if the lawsuit is successful [5].